Roy S. Herbst

Roy Herbst is a leader in thoracic oncology and immunotherapy clinical development. He has led practice-changing clinical trials in lung cancer, including pivotal studies of EGFR inhibitors and checkpoint immunotherapy combinations. Herbst is particularly known for his work on biomarker-driven treatment selection and has contributed to multiple FDA approvals in lung cancer.

Roy Herbst是胸部肿瘤学和免疫治疗临床开发的领导者。他领导了肺癌领域改变实践的临床试验，包括EGFR抑制剂和检查点免疫治疗组合的关键研究。Herbst以其在生物标志物驱动的治疗选择方面的工作而闻名，并为肺癌领域的多个FDA批准做出了贡献。